Zealand Pharma A/S (CPH:ZEAL)
371.50
-3.20 (-0.85%)
Jun 23, 2025, 11:25 AM CET
Zealand Pharma Revenue
Zealand Pharma had revenue of 8.09M DKK in the quarter ending March 31, 2025, a decrease of -46.37%. This brings the company's revenue in the last twelve months to 55.69M, down -83.82% year-over-year. In the year 2024, Zealand Pharma had annual revenue of 62.69M, down -81.71%.
Revenue (ttm)
55.69M
Revenue Growth
-83.82%
P/S Ratio
477.58
Revenue / Employee
144.66K
Employees
335
Market Cap
26.60B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 62.69M | -280.10M | -81.71% |
Dec 31, 2023 | 342.79M | 238.80M | 229.65% |
Dec 31, 2022 | 103.99M | -4.56M | -4.20% |
Dec 31, 2021 | 108.55M | -83.46M | -43.47% |
Dec 31, 2020 | 192.00M | 150.67M | 364.52% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Novo Nordisk | 303.14B |
Coloplast | 27.79B |
Genmab | 22.30B |
Demant | 22.42B |
ALK-Abelló | 5.71B |
H. Lundbeck | 22.95B |
Ambu A/S | 5.83B |
Embla Medical | 5.92B |
Zealand Pharma News
- 4 days ago - Zealand Pharma Obesity Therapy Shows Positive Trial Results - Market Watch
- 4 days ago - Zealand Pharma announces positive topline results from 28-week Phase 1b trial with GLP-1/GLP-2 receptor dual agonist dapiglutide - GlobeNewsWire
- 16 days ago - Zealand Pharma increases its share capital as a result of the exercise of employee warrants - GlobeNewsWire
- 21 days ago - Zealand Pharma submits Marketing Authorization Application to the European Medicines Agency for glepaglutide in short bowel syndrome - GlobeNewsWire
- 26 days ago - Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons - GlobeNewsWire
- 27 days ago - European stocks edge higher after Trump delays 50% tariffs on EU - CNBC
- 4 weeks ago - European stocks recover after Trump delays EU tariffs in hopes of deal - Reuters
- 4 weeks ago - Zealand Pharma continues to strengthen strategic leadership of innovation in obesity and related conditions with appointment of Steven Johnson as Chief Development Officer - GlobeNewsWire